Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel H van Raalte

Showing results (1-10 of 80) with videos related to

Pageof 8
Sort By:
Diabetes Research and Clinical Practice|August 26, 2011
Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?Daniel H van Raalte, Michaela Diamant
Frontiers in Pharmacology|May 20, 2022
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney FunctionDaniel H Van Raalte, Hiddo Lambers Heerspink
Atherosclerosis|April 26, 2022
Lipids in CKD: What do we actually know?Daniel Gordin, Petter Bjornstad, Daniel H van Raalte
European Journal of Pharmacology|June 23, 2015
About the gut microbiome as a pharmacological target in atherosclerosisJulia J Witjes, Daniel H van Raalte, Max Nieuwdorp
Journal of the American Society of Nephrology : JASN|September 17, 2025
Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered QuestionsHiddo J L Heerspink, Petter Bjornstad, David Cherney, et al.
Pharmaceutical Research|October 23, 2004
Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising futureDaniel H van Raalte, Min Li, P Haydn Pritchard, et al.
Diabetologia|May 7, 2014
Michaela Diamant, 11 April 1962-9 April 2014Robert J Heine, Hannele Yki-Järvinen, Steven E Kahn, et al.
British Journal of Anaesthesia|June 4, 2024
Risk of perioperative discontinuation of SGLT2 inhibitorsMaartina J P Oosterom-Eijmael, Jeroen Hermanides, Daniel H van Raalte, et al.
Endocrine Reviews|October 22, 2019
The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic ImplicationsYuliya Lytvyn, Petter Bjornstad, Daniel H van Raalte, et al.
BMJ Case Reports|August 15, 2015
Malignant cutaneous lesionsDaniel H van Raalte, Cathrien Beishuizen, Marloes D Stradmeijer, et al.
Pageof 8

Showing results (1-10 of 80) with videos related to

Sort By:
Pageof 8
Diabetes Research and Clinical Practice|August 26, 2011
Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?Daniel H van Raalte, Michaela Diamant
Frontiers in Pharmacology|May 20, 2022
Editorial: Sodium Glucose Co-Transporter 2 Inhibitors and Kidney FunctionDaniel H Van Raalte, Hiddo Lambers Heerspink
Atherosclerosis|April 26, 2022
Lipids in CKD: What do we actually know?Daniel Gordin, Petter Bjornstad, Daniel H van Raalte
European Journal of Pharmacology|June 23, 2015
About the gut microbiome as a pharmacological target in atherosclerosisJulia J Witjes, Daniel H van Raalte, Max Nieuwdorp
Journal of the American Society of Nephrology : JASN|September 17, 2025
Authors' Reply: Tirzepatide and Kidney Protection in Obesity: Unanswered QuestionsHiddo J L Heerspink, Petter Bjornstad, David Cherney, et al.
Pharmaceutical Research|October 23, 2004
Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising futureDaniel H van Raalte, Min Li, P Haydn Pritchard, et al.
Diabetologia|May 7, 2014
Michaela Diamant, 11 April 1962-9 April 2014Robert J Heine, Hannele Yki-Järvinen, Steven E Kahn, et al.
British Journal of Anaesthesia|June 4, 2024
Risk of perioperative discontinuation of SGLT2 inhibitorsMaartina J P Oosterom-Eijmael, Jeroen Hermanides, Daniel H van Raalte, et al.
Endocrine Reviews|October 22, 2019
The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic ImplicationsYuliya Lytvyn, Petter Bjornstad, Daniel H van Raalte, et al.
BMJ Case Reports|August 15, 2015
Malignant cutaneous lesionsDaniel H van Raalte, Cathrien Beishuizen, Marloes D Stradmeijer, et al.
Pageof 8